Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 6.50 Billion |
| USD 16.09 Billion | |
| % | |
|
Global Metastatic Melanoma Market, By Diagnosis (Physical Examination, Biopsy and Imaging Test), Treatment (Chemotherapy, Radiation, Surgery and Others), Route of Administration (Oral, Parenteral, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
The metastatic melanoma market is expected to witness significant growth during the forecast period. According to WHO, about 132,000 skin cancer cases occur annually. There has been a 10% decrease in ozone levels is projected to lead to a rise of 4,500 skin cancer cases worldwide. Early detection of melanoma helps in the treatment and increase survival rates. The rare genetic conditions such as xeroderma pigmentosum also increase the risk of melanoma and it is diagnosed with the biopsy of any skin lesion.
Data Bridge Market Research analyses a growth rate in the metastatic melanoma market in the forecast period 2022-2029. The expected CAGR of metastatic melanoma market is tend to be around 12% in the mentioned forecast period. The market was valued at USD 6.5 billion in 2021, and it would grow upto USD 16.09 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Physical Examination, Biopsy and Imaging Test), Treatment (Chemotherapy, Radiation, Surgery and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A. (France), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Melanoma is a kind of skin cancer wherein cancerous cells develops in pigment-producing cells called melanocytes. It can also affect in eyes and very rarely in the nose or throat. Patient suffering from the melanoma generally develops unusual growth in an existing mole. Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when the melanoma penetrates the skin and reaches several other parts of the body. People staying at high altitudes or close to the equator are at greater risk of melanoma due to high exposure to UV radiation.
Drivers
Recently, there have been some promising and innovative developments in the global melanoma market. The market has observed the presence of several noticeable market players with each of the players competing for more revenue and greater reach. Relentless research and development activities has played a critical role in the expansion of the share of the market and growing revenue for the market players. This boosts the market growth.
As per the records of WHO, around 132,000 cases of skin cancer occur each year. Furthermore, a 10% reduction in ozone levels is predicted to lead to an increase of 4,500 skin cancer cases worldwide. This is projected to increase the demand for these drugs during the forecast period.
Opportunities
The presence of large patient pool, having a strong presence of key players, ease of drug availability, a well-established healthcare infrastructure, favorable reimbursement policies in the healthcare system, rise in R&D, and innovation activities and higher adoption of advanced therapeutics may create opportunities for the market.
The major market players in the U.S., Europe, and Asia Pacific which are focusing on the development of new biologics for the treatment of melanoma. For instance, in March 2017, Take a Novel Challenge for Drug Discovery (TaNeDS) was introduced by Daiichi Sankyo Company Limited, as a type of collaborative project aimed at facilitating new drug development through collaborations. In addition, it has a strategic research partnership with AgonOX, Inc. to explore innovative immunotherapy medications for the immuno-oncology market.
Restraints/Challenges
To treat conditions that are rare, many times all treatments are not available, especially in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it hampers the market growth.
The huge expenditure associated with the several treatment methods such as chemotherapy, and targeted therapy which are in high demand in recent years hamper the market growth.
This metastatic melanoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the metastatic melanoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The pandemic has significantly affected numerous diagnostic methods because of several restrictions and risk exposure of comorbidity patients. A drastic decrease in skin biopsies was seen early in the COVID-19 pandemic, which unreasonably affected the elderly, females, and certain geographic regions. However, efforts have been made by the government to contain the situation in the post-pandemic era.
Recent Development:
In 2020, FDA approved the drug selumetinib of AstraZeneca and Merck & Co. to treat neurofibromatosis type 1, or NF1, a rare and characteristically inherited disease that causes tumors to grow inside nerve sheaths. In addition to this, Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.
The metastatic melanoma market is segmented on the basis of diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
Treatment
Route of Administration
End User
Distribution Channel
The global metastatic melanoma market is analyzed and market size insights and trends are provided by diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global metastatic melanoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global metastatic melanoma market throughout the forecasted period due to the increased prevalence of melanoma and increasing investment in healthcare segment.
North America dominates the market due to latest technology development and presences of variety of innovative drug molecule to enhance the treatment procedure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The metastatic melanoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to metastatic melanoma market.
Key players operating in the metastatic melanoma market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.